MET and non-small cell lung carcinoma: Recently, it has been proved that MET combined with PD-1 inhibitor enhanced anti-tumor efficacy in STK11 mutant NSCLC through inhibition of STING ubiquitination [28], suggesting a positive pro-immune effect of MET in patients with poor response to immunotherapy.